[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371497-105":59,"doc-detail-371497-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","unlocking-the-lipid-code-srebps-as-key-drivers-in-gastrointestinal-tumour-metabolism","Unlocking the lipid code - SREBPs as key drivers in gastrointestinal tumour metabolism","","Metabolic reprogramming is increasingly recognized as a driver of gastrointestinal (GI) malignancies. As central regulators of lipid metabolism, sterol regulatory element binding proteins (SREBPs) link dietary metabolic cues and carcinogenic stimuli through subtype-specific mechanisms, promoting malignant phenotypes. This review outlines SREBP molecular background, structure, and posttranscriptional regulatory networks, then analyzes activation patterns across liver, gastric, colorectal, and other GI cancers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unlocking-the-lipid-code-srebps-as-key-drivers-in-gastrointestinal-tumour-metabolism/371497/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unlocking-the-lipid-code-srebps-as-key-drivers-in-gastrointestinal-tumour-metabolism/371497.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are SREBPs considered key drivers in gastrointestinal tumour metabolism?","Question",{"text":113,"@type":114},"SREBPs integrate metabolic signals and carcinogenic stimuli through subtype-specific mechanisms, promoting malignant tumour lipid reprogramming and phenotypes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does the review cover about SREBPs?",{"text":118,"@type":114},"It presents the molecular background, structural characteristics, and posttranscriptional regulatory networks of SREBPs, followed by analyses of distinct activation patterns across GI cancers.",{"name":120,"@type":111,"acceptedAnswer":121},"What targeted intervention strategies are discussed for SREBP subtypes?",{"text":122,"@type":114},"The review describes small molecule inhibitors (e.g., fatostatin), natural compounds (e.g., berberine via AMPK/mTOR modulation), and statin-mediated mevalonic acid pathway inhibition, aiming to improve responses to chemotherapy and chemoradiotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},371497,1790215747,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Tang et al. Lipids in Health and Disease (2025) 24:190  \n[https://doi.org/10.1186/s12944-025-02612-8](https://doi.org/10.1186/s12944-025-02612-8)  \nLipids in Health and Disease  \n REVIEW Open Access  \nUnlocking the lipid code: SREBPs as key   drivers in gastrointestinal tumour metabolism  \nHaowen Tang1, Yuting Zhang1, Danni Zhao1, Minjie Guo1, Xiao Yuan2* and Xu Wang1*  \nAbstract  \nIn recent years, metabolic reprogramming has emerged as a significant breakthrough in elucidating the onset and progression of gastrointestinal (GI) malignancies. As central regulatory hubs for lipid metabolism, sterol regulatory element binding proteins (SREBPs) integrate dietary metabolic signals and carcinogenic stimuli through subtypespecific mechanisms, thereby promoting malignant tumour phenotypes. In this review, we first present the molecular background, structural characteristics, and posttranscriptional regulatory networks associated with SREBPs. We subsequently describe a systematic analysis of the distinct activation patterns of SREBPs in liver, gastric, colorectal, and other gastrointestinal cancers. Furthermore, we explore targeted intervention strategies for different SREBP subtypes, including small molecule inhibitors (such as fatostatin, which inhibits SREBP cleavage), natural compounds (such as berberine, which modulates the AMPK/mTOR pathway), and statin-mediated inhibition of the mevalonic acid pathway. These strategies may enhance tumour cell sensitivity to chemotherapeutic agents (such as 5-FU, gezil, and tabine) and improve the response to synergistic chemoradiotherapy by reversing adaptive metabolic resistance driven by the tumour microenvironment. Through this review, we hope to provide new insights into precise interventions targeting various subtypes of the SREBP molecule.  \nKeywords SREBPs, GI tumours, Lipid metabolism reprogramming, Lipogenesis, Targeted therapy  \nIntroduction  \nGastrointestinal (GI) tumours, which include malignancies such as oesophageal, stomach, colorectal, pancreatic, and liver cancer, have emerged as prevalent, life-threatening diseases that significantly impact quality of life in humans [1–4]. Although the pathogenesis of GI tumours remains largely elusive, modifications in lipid metabolism have been identified as distinctive characteristics of this type of cancer. Increasing attention has also been given to changes in lipid metabolism in cancer [5, 6]. Cancer cells rely on significant lipid synthesis and uptake to support  \n*Correspondence:  \nXiao Yuan [yuanxiao07seven@163.com](yuanxiao07seven@163.com)[ ](yuanxiao07seven@163.com)Xu Wang  \n[jsdxwx@126.com](jsdxwx@126.com)  \n1 Department of Thoracic Oncology, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China  \n2 Cancer Institute of Jiangsu University, Zhenjiang, China  \ntheir replication. A diverse array of enzymes, proteins, and transcription factors are involved in the reprogramming of lipid metabolism in GI tumours [6, 7]. These molecules, when expressed abnormally, can enhance lipid production and promote the clustering of lipid droplets through various mechanisms, thus affecting the development, spread, and growth of GI tumours.  \nSterol regulatory element-binding proteins (SREBPs) serve as primary regulators of lipogenesis and significantly contribute to the maintenance of appropriate cellular lipid levels, including triglycerides and sterols, via intricate proteolytic processing mechanisms [8]. When highly expressed, SREBPs have been observed to be instrumental in lipid reprogramming across a diverse range of cancers [9]. Recent research has indicated a notable increase in lipid synthesis and uptake within gastrointestinal tumours, and this factor substantiates tumour growth. The range of cancers affected by the high expression of SREBPs includes prostate, liver, colorectal,  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDeriva","cbCaidHpMnCl4DiR","https://ap.wps.com/l/cbCaidHpMnCl4DiR","pdf",1594397,18,"English","# Abstract\n# Introduction\n## Lipid metabolism and GI tumour characteristics\n## Role of SREBPs in lipogenesis and lipid reprogramming\n# Review Scope and Methods\n## Search strategy and SREBP subtypes","[{\"question\":\"Why are SREBPs considered key drivers in gastrointestinal tumour metabolism?\",\"answer\":\"SREBPs integrate metabolic signals and carcinogenic stimuli through subtype-specific mechanisms, promoting malignant tumour lipid reprogramming and phenotypes.\"},{\"question\":\"What does the review cover about SREBPs?\",\"answer\":\"It presents the molecular background, structural characteristics, and posttranscriptional regulatory networks of SREBPs, followed by analyses of distinct activation patterns across GI cancers.\"},{\"question\":\"What targeted intervention strategies are discussed for SREBP subtypes?\",\"answer\":\"The review describes small molecule inhibitors (e.g., fatostatin), natural compounds (e.g., berberine via AMPK/mTOR modulation), and statin-mediated mevalonic acid pathway inhibition, aiming to improve responses to chemotherapy and chemoradiotherapy.\"}]","Unlocking the lipid code - SREBPs as key drivers in gastrointestinal tumour metabolism | PDF",1790192212,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbee17eb21d4f1ba36e56052d9142eb7.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80f168392ff3289a0882d86c4371418a.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6df1f7e36c0c4b2890909d092f6aa3a.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dac0badb224ffa4f236c990b1e7df1e.webp",980,1301]